CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months

CytoDyn Inc.

Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
Shares priced at 98% of lowest 3-day VWAP; Yorkville capped at 4.99% beneficial ownership.
Commitment fee of 1% paid in shares (half immediately, half at 6 months); structuring fee $25k.
Proceeds for working capital, debt repayment, and leronlimab PD-L1 program development.
No warrants or derivatives; registration statement to be filed for resale.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.